Skip to content
2000
image of Development of Satranidazole HCl-Loaded Oral Nanoparticulate Formulation for Colon Targeting and Colon Cancer Therapy Associated with Inflammatory Bowel Disease

Abstract

Background

Colon-targeted drug delivery is a crucial area of research aimed at treating local disorders like IBD, including ulcerative colitis and Crohn's disease. By delivering drugs directly to the colon, this approach enhances therapeutic efficacy and minimizes systemic toxicity. Nanoparticles are an effective vehicle for controlled drug delivery, improving treatment outcomes for colon-specific diseases.

Objective

The study aimed to develop an oral nanoparticulate formulation of Satranidazole (STZ) using a solvent evaporation technique for colonic targeting and characterize its physicochemical properties, compatibility, and drug release profile.

Methods

Using a modified solvent evaporation method, STZ-loaded nanoparticles (STZ-NPs) were formulated using Eudragit RS100 and RL100 polymers. Preformulation studies, including FT-IR and DSC, were performed to confirm the compatibility between the drug and polymers. The nanoparticles were evaluated in terms of entrapment efficiency, particle size, zeta potential, polydispersity index, and drug release study.

Results

The optimized formulation (F3) demonstrated the highest entrapment efficiency (83.55%) with particle sizes ranging from 107.9 nm to 302 nm and a zeta potential between -34.25 mV and +48.8 mV. drug release studies showed controlled release over 16 hours, with the optimized batch achieving 95.85% drug release, indicating effective accumulation in the inflamed colon.

Conclusion

The Satranidazole-loaded nanoparticles, containing time- and pH-dependent polymers, successfully inhibited premature drug release in acidic environments and provided controlled release at colonic pH. Thus, this delivery system shows promise as an effective treatment for IBD, offering targeted drug release and reduced systemic toxicity.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128368738250414070421
2025-05-07
2025-09-04

  • From This Site

    /content/journals/cpd/10.2174/0113816128368738250414070421
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kaplan G.G. Ng S.C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017 152 2 313 321.e2 10.1053/j.gastro.2016.10.020 27793607
    [Google Scholar]
  2. Kaplan G.G. Windsor J.W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2021 18 1 56 66 10.1038/s41575‑020‑00360‑x 33033392
    [Google Scholar]
  3. Su H.J. Chiu Y.T. Chiu C.T. Lin Y.C. Wang C.Y. Hsieh J.Y. Wei S.C. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J. Formos. Med. Assoc. 2019 118 7 1083 1092 10.1016/j.jfma.2018.07.005 30054112
    [Google Scholar]
  4. Bernstein C.N. Eliakim A. Fedail S. Fried M. Gearry R. Goh K.L. Hamid S. Khan A.G. Khalif I. Ng S.C. Ouyang Q. Rey J.F. Sood A. Steinwurz F. Watermeyer G. LeMair A. Review Team World gastroenterology organization global guidelines inflammatory bowel disease: Update August 2015. J. Clin. Gastroenterol. 2016 50 10 803 818 10.1097/MCG.0000000000000660 27741097
    [Google Scholar]
  5. Sýkora J. Pomahačová R. Kreslová M. Cvalínová D. Štych P. Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J. Gastroenterol. 2018 24 25 2741 2763 10.3748/wjg.v24.i25.2741 29991879
    [Google Scholar]
  6. McCoubrey L.E. Favaron A. Awad A. Orlu M. Gaisford S. Basit A.W. Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics. J. Control. Release 2023 353 1107 1126 10.1016/j.jconrel.2022.12.029
    [Google Scholar]
  7. Russo T. Peluso V. Gloria A. Oliviero O. Rinaldi L. Improta G. De Santis R. D’Antò V. Combination design of time-dependent magnetic field and magnetic nanocomposites to guide cell behavior. Nanomaterials 2020 10 3 577 10.3390/nano10030577 32235724
    [Google Scholar]
  8. Ghosh S. Basak A. Ganguly D. Porey A. Design, fabrication, in vitro, and ex-vivo permeation study of micro-emulsified hydrogel of fluconazole (mhg-flcz) using a central composite design (CCD). J. Appl. Pharm. 2024 16 2 66 75 10.22159/ijap.2024v16i2.49865
    [Google Scholar]
  9. Kesarwani S. Parihar S. Singh S. Gautam A. Pandey A. Anjum M.M. A new era of Nano!!! Comparative evaluation of ganglioside polymeric nanoparticle coated satranidazole gel and 1% metronidazole gel for the treatment of periodontitis. J. Indian Soc. Periodontol. 2022 26 4 378 383 10.4103/jisp.jisp_233_21 35959308
    [Google Scholar]
  10. Shah M.K.A. Azad A.K. Nawaz A. Ullah S. Latif M.S. Rahman H. Alsharif K.F. Alzahrani K.J. El-Kott A.F. Albrakati A. Abdel-Daim M.M. Formulation development, characterization and antifungal evaluation of chitosan NPs for topical delivery of voriconazole in vitro and ex vivo. Polymers 2021 14 1 135 10.3390/polym14010135 35012154
    [Google Scholar]
  11. Ho H.N. Le H.H. Le T.G. Duong T.H.A. Ngo V.Q.T. Dang C.T. Nguyen V.M. Tran T.H. Nguyen C.N. Formulation and characterization of hydroxyethyl cellulose-based gel containing metronidazole-loaded solid lipid nanoparticles for buccal mucosal drug delivery. Int. J. Biol. Macromol. 2022 194 1010 1018 10.1016/j.ijbiomac.2021.11.161 34843817
    [Google Scholar]
  12. Rasmussen M.K. Pedersen J.N. Marie R. Size and surface charge characterization of nanoparticles with a salt gradient. Nat. Commun. 2020 11 1 2337 10.1038/s41467‑020‑15889‑3 32393750
    [Google Scholar]
  13. Wu K.W. Sweeney C. Dudhipala N. Lakhani P. Chaurasiya N.D. Tekwani B.L. Majumdar S. Primaquine loaded solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nanoemulsion (NE): Effect of lipid matrix and surfactant on drug entrapment, in vitro release, and ex vivo hemolysis. AAPS PharmSciTech 2021 22 7 240 10.1208/s12249‑021‑02108‑5 34590195
    [Google Scholar]
  14. Turanlı Y. Acartürk F. Preparation and characterization of colon-targeted pH/Time-dependent nanoparticles using anionic and cationic polymethacrylate polymers. Eur. J. Pharm. Sci. 2022 171 106122 10.1016/j.ejps.2022.106122 35007712
    [Google Scholar]
  15. Alshammari N.D. Elkanayati R. Vemula S.K. Al Shawakri E. Uttreja P. Almutairi M. Repka M.A. Advancements in colon-targeted drug delivery: A comprehensive review on recent techniques with emphasis on hot-melt extrusion and 3D printing technologies. AAPS PharmSciTech 2024 25 7 236 10.1208/s12249‑024‑02965‑w 39379609
    [Google Scholar]
  16. Mazumder R. Mahanti B. Majumdar S. Pal R. Pahari N. Satranidazole-loaded chitosan/locust bean gum/xanthan gum polysaccharide composite multiunit pellets for colon targeting: In vitro–in vivo investigation. Beni. Suef Univ. J. Basic Appl. Sci. 2022 11 1 151 10.1186/s43088‑022‑00333‑w
    [Google Scholar]
  17. Zielińska A. Ferreira N.R. Feliczak-Guzik A. Nowak I. Souto E.B. Loading, release profile and accelerated stability assessment of monoterpenes-loaded solid lipid nanoparticles (SLN). Pharm. Dev. Technol. 2020 25 7 832 844 10.1080/10837450.2020.1744008 32204628
    [Google Scholar]
  18. Bhattacharya S. Anjum M.M. Patel K.K. Gemcitabine cationic polymeric nanoparticles against ovarian cancer: Formulation, characterization, and targeted drug delivery. Drug Deliv. 2022 29 1 1060 1074 10.1080/10717544.2022.2058645 35363113
    [Google Scholar]
  19. El Sayeh F Abou El Ela A. Abbas Ibrahim M. Alqahtani Y. Almomen A. Sfouq Aleanizy F. Fluconazole nanoparticles prepared by antisolvent precipitation technique: Physicochemical, in vitro, ex vivo and in vivo ocular evaluation. Saudi Pharm. J. 2021 29 6 576 585 10.1016/j.jsps.2021.04.018 34194264
    [Google Scholar]
  20. Yeshi K. Ruscher R. Hunter L. Daly N.L. Loukas A. Wangchuk P. Revisiting inflammatory bowel disease: Pathology, treatments, challenges and emerging therapeutics including drug leads from natural products. J. Clin. Med. 2020 9 5 1273 10.3390/jcm9051273 32354192
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128368738250414070421
Loading
Development of Satranidazole HCl-Loaded Oral Nanoparticulate Formulation for Colon Targeting and Colon Cancer Therapy Associated with Inflammatory Bowel Disease
Bentham Science Publishers ; https://doi.org/10.2174/0113816128368738250414070421
/content/journals/cpd/10.2174/0113816128368738250414070421
/content/journals/cpd/10.2174/0113816128368738250414070421
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: pH-dependent ; Inflammatory bowel disease ; controlled drug release ; nanoparticulate ; polydispersity index ; Satranidazole

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test